non-Hodgkin lymphoma Archives

Novartis’ CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few

Novartis’ bid to extend Kymriah into earlier use hits a roadblock

https://pharmaphorum.com/news/novartis-bid-to-extend-kymriah-into-earlier-use-hits-a-roadblock/

News/ News/ Oncology

Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCL

Phil Taylor antibody-drug conjugate, DLBCL, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, Roche 0 Comment

Roche has the results it was hoping for in a phase 3 trial of Polivy in newly diagnosed

Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCL

https://pharmaphorum.com/news/armed-with-ph3-trial-roche-preps-filing-for-polivy-in-first-line-dlbcl/

News/ News/ Oncology

BMS will file for earlier-line use of Breyanzi in lymphoma after trial win

Phil Taylor Breyanzi, Bristol-Myers Squibb, CAR-T therapies, diffuse B-Cell lymphoma, Haematology, non-Hodgkin lymphoma 0 Comment

Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but

BMS will file for earlier-line use of Breyanzi in lymphoma after trial win

https://pharmaphorum.com/news/bms-will-file-for-earlier-line-use-of-breyanzi-in-lymphoma-after-trial-win/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ Oncology

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

Richard Staines Allogene, CAR T, Gilead, Kite Pharma, non-Hodgkin lymphoma, Oncology 0 Comment

In 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

https://pharmaphorum.com/news/allogene-announces-pivotal-trial/

News/ News/ Oncology

BMS finally gets FDA OK for liso-cel, sets $410k launch price

Phil Taylor Breyanzi, Bristol-Myers Squibb, Celgene, cell therapy, DLBCL, immuno-oncology, liso-cel, non-Hodgkin lymphoma, Oncology, TG Therapeutics, Ukoniq 0 Comment

Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US

BMS finally gets FDA OK for liso-cel, sets $410k launch price

https://pharmaphorum.com/news/bms-finally-gets-fda-ok-for-liso-cel-sets-410k-launch-price/

News/ News/ Oncology

ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma

Phil Taylor AbbVie, American Society of Haematology, BTK inhibitor, Eli Lilly, Imbruvica, Johnson & Johnson, non-Hodgkin lymphoma 0 Comment

Eli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has

ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma

https://pharmaphorum.com/news/ash-lilly-builds-case-for-its-btk-drug-loxo-305-in-lymphoma/

News/ News/ Oncology

FDA sets May date for verdict on ADC’s lymphoma drug Lonca

Phil Taylor ADC Therapeutics, antibody-drug conjugate, CART, diffuse B-Cell lymphoma, loncastuximab tesirine, non-Hodgkin lymphoma 0 Comment

ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a

FDA sets May date for verdict on ADC’s lymphoma drug Lonca

https://pharmaphorum.com/news/fda-sets-may-date-for-verdict-on-adcs-lymphoma-drug-lonca/

News/ News/ Oncology/ Top stories

Merck & Co buys cancer biotech VelosBio for $2.75bn

Richard Staines breast cancer, cancer, lung cancer, Merck & Co, non-Hodgkin lymphoma 0 Comment

Merck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion

Merck & Co buys cancer biotech VelosBio for $2.75bn

https://pharmaphorum.com/news/merck-co-buys-cancer-biotech-velosbio-for-2-75bn/

Market Access/ News/ News

NICE recommends regular NHS funding for Roche’s lymphoma drug Polivy

Richard Staines cancer, market access, NICE, non-Hodgkin lymphoma, Polivy, Roche 0 Comment

NICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning

NICE recommends regular NHS funding for Roche’s lymphoma drug Polivy

https://pharmaphorum.com/news/nice-recommends-regular-nhs-funding-for-roches-lymphoma-drug-polivy/

Trending

non-Hodgkin lymphoma

Login